How to Get GLP-1 for Weight Loss: A Comprehensive Guide

Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Getting a GLP-1 medication for weight loss comes down to a clinical evaluation, a prescription written for an approved indication where one applies, and a decision about how you will pay. The step people skip is the first one: identifying which product is actually approved for weight management. Wegovy and Zepbound carry weight-management indications. Ozempic and Mounjaro do not — both are type 2 diabetes products. Starting from the right product shortens every conversation that follows.

Step One: Know Which Products Are Approved for Weight Management

Wegovy injection is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. It also carries a cardiovascular risk reduction indication and an accelerated-approval indication in noncirrhotic MASH.

Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.

Wegovy tablets exist as well, indicated in adults for cardiovascular risk reduction and for weight reduction. There is no FDA-approved oral tirzepatide product.

Step Two: The Clinical Evaluation

A prescriber needs your weight and height, your medical history, your current medications and your family history. The screening that matters most is for the boxed warning: every semaglutide and tirzepatide label contraindicates use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Other history that changes the conversation includes pancreatitis, gallbladder disease, severe gastrointestinal disease — the Ozempic label states it is not recommended in patients with severe gastroparesis — diabetic retinopathy, kidney impairment, and pregnancy or planned pregnancy. The Ozempic label directs discontinuation in women at least two months before a planned pregnancy because of semaglutide’s long washout period.

Concomitant medications matter too. The labels advise caution with oral medications because delayed gastric emptying may affect their absorption, and the Wegovy label goes further, directing increased clinical or laboratory monitoring for oral drugs with a narrow therapeutic index.

Step Three: What the Trials Actually Showed

Set expectations against published results rather than anecdotes. In Wegovy Study 2, a 68-week trial that enrolled 1,961 patients with obesity or with overweight plus at least one weight-related comorbid condition and excluded type 2 diabetes, mean percent change in body weight was −14.9% with Wegovy injection versus −2.4% with placebo.

In SURMOUNT-1, a 72-week trial in 2,539 adults, mean weight changes were −15.0%, −19.5% and −20.9% across the three tirzepatide doses studied versus −3.1% with placebo. In SURMOUNT-5, a 72-week head-to-head trial in 751 adults, the result was −20.2% with tirzepatide versus −13.7% with semaglutide.

Every one of those figures is a group average produced alongside a structured diet and activity programme. In the Wegovy trials participants received instruction for an approximately 500 kcal per day deficit and counselling toward a minimum of 150 minutes of physical activity per week.

Step Four: Decide How You Will Pay

Insurance coverage for weight management is inconsistent. Many plans carry a categorical exclusion for anti-obesity medications, which is a benefit-design decision rather than a clinical one and generally cannot be appealed on clinical grounds. Ask your plan in writing whether the category is excluded before investing effort in documentation.

Where coverage exists, prior authorization typically requires documented body mass index, documented weight-related conditions and evidence of prior structured lifestyle intervention. Manufacturer savings and direct-purchase programs are a separate channel with their own eligibility rules that change frequently and should be verified at the source.

Where Compounded Preparations Fit

Compounded semaglutide and tirzepatide are prepared by licensed pharmacies against individual prescriptions and are not FDA-approved finished products. The FDA is explicit that compounded drugs are not FDA approved and that it does not review them for safety, effectiveness or quality before marketing.

The agency has also published specific concerns for this class, including adverse event reports that may relate to dosing errors, the finding that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients than those in approved drugs, and complaints about products arriving warm or with inadequate refrigeration.

None of that makes the category illegitimate. It means the pharmacy’s licensure, the prescriber’s involvement and the ability to reach a clinician afterward are the things worth verifying.

What Happens After You Start

These are chronic therapies. The labels direct that treatment response and tolerability be considered when selecting a maintenance dosage, which presupposes ongoing contact with a prescriber rather than a single transaction.

The discontinuation literature is consistent and worth knowing in advance. Randomised withdrawal trials in this class show substantial weight regain after therapy stops, which reviewers increasingly frame as disease recurrence in a chronic relapsing condition rather than as treatment failure. Planning for the long term is part of starting well.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Which GLP-1 medications are FDA approved for weight loss?

Wegovy injection and Wegovy tablets carry weight-reduction indications, and Zepbound is indicated for long-term weight reduction and for moderate to severe obstructive sleep apnea in adults with obesity. Ozempic and Mounjaro are type 2 diabetes products with no weight-management indication in their labeling. Orforglipron, approved April 1 2026, is an oral product indicated for chronic weight management.

Do I need a diagnosis of obesity to be prescribed one?

The labeled populations are defined by obesity, or by overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. Whether you fall inside a labeled population is a clinical determination made by a prescriber who has your measurements, history and current medications, not something an article can establish.

How much weight did people lose in the trials?

In Wegovy Study 2, a 68-week trial excluding type 2 diabetes, mean change in body weight was minus 14.9% with Wegovy injection versus minus 2.4% with placebo. In SURMOUNT-1, a 72-week trial in 2,539 adults, mean changes were minus 15.0%, minus 19.5% and minus 20.9% across three tirzepatide doses versus minus 3.1% with placebo. These are group averages, not individual forecasts.

What disqualifies someone from this class of medication?

The labels contraindicate use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in people with serious hypersensitivity to the active ingredient or excipients. History of pancreatitis, gallbladder disease, severe gastroparesis, diabetic retinopathy and pregnancy all change the assessment. That evaluation belongs to a prescriber.

Will I regain the weight if I stop?

Randomised withdrawal trials across this class consistently show substantial weight regain after discontinuation, along with reversal of some cardiometabolic improvements. Recent reviews frame this as recurrence of a chronic relapsing condition once pharmacological appetite suppression is removed, rather than as failure of the treatment. Discuss a long-term plan with your prescriber before starting.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.